ORIC Stock Analysis: Buy, Sell, or Hold?
ORIC - Oric Pharmaceuticals, Inc. Common Stock
$14.65
0.73 (5.24%)
▲
5d:
+6.55%
30d:
+35.27%
90d:
+83.81%
WAIT
LOW Confidence
Analysis Updated: Aug 19, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When ORIC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ORIC shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ORIC shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: ORIC is currently trading at $14.65, which is considered extended relative to its 30-day fair value range of $10.80 to $13.52.
Technical Outlook: Technically, ORIC is in a uptrend. The price is approaching resistance at $14.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: ORIC scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+57.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ORIC is in a uptrend. The price is approaching resistance at $14.68. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 5.2% recently.
Market Sentiment: ORIC scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $21.00 (+57.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$10.80 -
$13.52
Company Quality Score
31/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.3%
All Signals
- BEARISH: Price extended above range (+8.4% above its trading range)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.2%)
- BULLISH: Trading 57.0% below Wall St target ($21.00)
- WARNING: Composite score 31/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$10.80 -
$13.52
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$12.74
Resistance Level
$14.68
Current Trend
Uptrend
Technical data as of
Aug 19, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-8.17
Wall Street Target
$21.00
(+57.0%)
Share & Embed Analysis
Last updated: August 20, 2026 1:23 AM ET
Data refreshes hourly during market hours. Next update: 2:23 AM
Data refreshes hourly during market hours. Next update: 2:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ORIC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Dominic Piscitelli
SELL
52000 shares
2026-02-24
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 71 BUY |
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 35 SELL |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 53 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 65 BUY |
